Table 1.
The Association Between TPM2 and Clinicopathological Parameters
| Variables | Total | TPM2 status | P Value | |
|---|---|---|---|---|
| Low | High | |||
| Age | ||||
| ≥60 | 48 | 23 (47.9) | 25 (52.1) | >0.9999 |
| <60 | 107 | 52 (48.6) | 55 (51.4) | |
| Tumor size(cm) | ||||
| <2 | 66 | 26 (39.4) | 40 (60.6) | 0.1160 |
| 2–5 | 86 | 48 (55.8) | 38 (44.2) | |
| >5 | 3 | 1 (33.3) | 2 (66.7) | |
| Lymph node metastases | ||||
| Negative | 89 | 28 (31.5) | 61 (68.5) | <0.001 |
| Positive | 66 | 47 (71.2) | 19 (28.8) | |
| Histological grading | ||||
| I+II | 93 | 36 (38.7) | 57 (61.3) | 0.0084 |
| III | 62 | 38 (61.3) | 24 (38.7) | |
| Molecular subtypes | ||||
| Luminal A | 23 | 8 (34.8) | 15 (65.2) | 0.5366 |
| Luminal B | 108 | 55 (50.9) | 53 (49.1) | |
| HER2-enriched | 11 | 6 (54.5) | 5 (45.5) | |
| Triple negative | 13 | 6 (46.2) | 7 (53.8) | |
| Ki67 (%) | ||||
| <14 | 24 | 8 (33.3) | 16 (66,7) | 0.1242 |
| ≥14 | 131 | 67 (51.1) | 64 (48.9) | |
| HER2 | ||||
| 0 | 27 | 10 (37.0) | 17 (63.0) | 0.2473 |
| 1+ | 40 | 17 (42.5) | 23 (57.5) | |
| 2+ | 58 | 31 (53.4) | 27 (46.6) | |
| 3+ | 30 | 18 (60.0) | 12 (40.0) | |
Notes: the italicized and bold text (<0.001, 0.0084) indicates statistically significant.
Abbreviation: HER2, human epidermal growth factor receptor 2.